The Revised International Prognostic Scoring System (IPSS-R) has been recognized as the score with the best outcome prediction capability in MDS, but this brought new concerns about the accurate prognostication of patients classified into the intermediate risk category. The correct enumeration of blasts is essential in prognostication of MDS. Recent data evidenced that considering blasts from nonerythroid cellularity (NECs) improves outcome prediction in the context of IPSS and WHO classification. We assessed the percentage of blasts from total nucleated cells (TNCs) and NECs in 3924 MDS patients from the GESMD, 498 of whom were MDS with erythroid predominance (MDS-E). We assessed if calculating IPSS-R by enumerating blasts from NECs improves prognostication of MDS. Twenty-four percent of patients classified into the intermediate category were reclassified into higher-risk categories and showed shorter overall survival (OS) and time to AML evolution than those who remained into the intermediate one. Likewise, a better distribution of patients was observed, since lower-risk patients showed longer survivals than previously whereas higher-risk ones maintained the outcome expected in this poor prognostic group (median OS < 20 months). Furthermore, our approach was particularly useful for detecting patients at risk of dying with AML. Regarding MDS-E, 51% patients classified into the intermediate category were reclassified into higher-risk ones and showed shorter OS and time to AML. In this subgroup of MDS, IPSS-R was capable of splitting our series in five groups with significant differences in OS only when blasts were assessed from NECs. In conclusion, our easy-applicable approach improves prognostic assessment of MDS patients.
| I N T R O D U C T I O N
A proper prognostic stratification of patients diagnosed with myelodysplastic syndrome (MDS) is of major clinical relevance, since the choice of treatment is risk-adapted. The correct enumeration of blasts is essential in the diagnostic and prognostic evaluation of MDS. Proportion of bone marrow (BM) blasts has been demonstrated as an independent prognostic factor in MDS and is included in the most widely used prognostic scores:
the International Prognostic Scoring System (IPSS) and the revised IPSS (IPSS-R).
1,2 The IPSS-R has been recognized as the score with the best prognostic capability in MDS, [2] [3] [4] but some concerns exist about the real prognostic significance of the intermediate risk category. 2 Patients classified into this group showed an outcome closer to the expected in higherrisk MDS patients, presenting a median overall survival (OS) around 30 months in different studies. [2] [3] [4] [5] [6] In this regard, the Spanish Group of Myelodysplastic Syndromes (GESMD) considers as higher-risk patients those with an expected median OS inferior to 30 months. 7, 8 In MDS with erythroid predominance (MDS-E), that are defined by the presence of equal or greater than 50% erythroblasts in BM, there was no consensus on the best method for enumerating BM blastsfrom total nucleated cells (TNCs) or from nonerythroid cellularity (NECs). Despite the lack of agreement, WHO 2008 recommendation was to consider blasts from TNCs once the diagnosis of erythroleukemia (presence of equal or greater than 20% BM blasts from NECs) was ruled out. 9 In the 2016 revision to the WHO classification of myeloid neoplasms, the nonerythroid blast cell count rule was eliminated. 10 Despite this recommendation, as shown in our recent study by Arenillas et al., 11 considering BM blasts from NECs improves the prognostic evaluation of MDS when applying IPSS and WHO classification, not only in patients with MDS-E but also in all patients with MDS. Some controversies have been generated about the convenience of applying this method, as this would imply an important change in the global paradigm of prognostication in MDS. In this regard, in a recent publication, Bennett et al did not found any advantage on applying this new approach even when this was assessed in the context of IPSS-R. 12 After the publication of these works showing contradictory findings, MDS experts claim for an unequivocal criterion in the way of counting BM blasts, as it is crucial for giving the best risk-adapted therapeutic option to patients diagnosed with MDS. 13 Due to this controversial data, evaluating the appropriateness of calculating IPSS-R by considering BM blasts from NECs is imperative. Currently, our group has complete information of the IPSS-R distribution on 3924 MDS patients. Our main aim was to evaluate whether considering BM blasts from NECs rather than from TNCs, as currently recommended, improves outcome prediction in MDS also in the context of IPSS-R, focusing on prognostication of patients classified into the intermediate risk category.
| P A T I E NT S A ND M E T H O DS

| Patients
At the completion of this report, the database of GESMD contained complete cytomorphologic, clinical, and follow-up information on 3924 We assessed outcome predicted by IPSS-R considering BM blasts from TNCs and from NECs (recoded IPSS-R). Five groups with significant differences in OS and time to AML progression were observed by using both methods ( Figure 1 , 71.7 months, P < .001; median time to AML evolution, 63 vs. not reached (NR) months, P < .001) (Supporting Information Figure S1 ). As expected, the majority of the upgraded patients belonged to the inter- Table S1 ). This finding reinforces the suitability of our method for detecting MDS patients with a higher propensity to develop AML. This is a nontrivial finding as AML transformation is closely related with disease evolution while survival could be influenced by several factors in this elderly population. Thus, by considering blasts from NECs we were able to detect a group of patients labeled at present as having lowerrisk disease but who presented an outcome much closer to that of higher-risk patients. The worse outcome observed in these reclassified patients was mainly influenced by the difference in the weight of blasts when assessed from NECs, as other prognostic factors that could explain this difference in outcome, as cytogenetics and depth of cytopenias, were adjusted by using IPSS-R.
Afterwards, IPSS and IPSS-R risk predictive accuracy for survival and time to AML evolution when considering blasts from TNCs or from NECs were evaluated. Interestingly, by using the CPE, the In a recent publication, Pfeilst€ ocker et al suggested a reasonable division into lower-and higher-risk MDS based on the IPSS-R at a cutoff of 3.5 points. 6 Interestingly, by applying the Maxstat, 18 3.5 points of the IPSS-R was also detected as the cutoff with the best capability to significantly split our series into two groups with different OS and time to AML evolution. By this approach, the majority of patients clas- We assessed OS and time to AML evolution predicted by IPSS-R considering BM blasts from TNCs and from NECs. Five groups with significant differences in OS were observed only by applying the recoded IPSS-R (Figure 2) . By using our approach, the median OS of Figure S2 ). 
| DISCUSSION
A proper prognostic stratification in MDS is essential for designing riskadapted therapeutic strategies than can range from watchful waiting to allogeneic stem cell transplantation. The design of improvement strategies in prognostic evaluation of patients with MDS is essential to help clinicians in risk-adapted therapeutic decisions. In the 2016 revision to the WHO classification of myeloid neoplasms, the nonerythroid blast cell count rule was eliminated. 10 Our results based on 3924 patients, 498 of whom were MDS with erythroid predominance (MDS-E), are not in line with this statement and evidence that enumerating BM blasts from NECs rather than from TNCs improves risk stratification of MDS. This is the largest series of MDS patients with information on BM erythroid precursor percentage to date.
As showed in our recent work, considering BM blasts from NECs improved outcome prediction in MDS when applying IPSS and WHO classification. 11 Despite the robustness of those findings, assessing the appropriateness of considering BM blasts from NECs in the context of IPSS-R seems crucial, since IPSS-R has been accepted as the score with the best prognostic capability in MDS.
As previously shown, enumerating BM blasts from NECs permitted us to upgrade to higher-risk categories 24% of patients previously classified into the intermediate risk category of IPSS-R. These upgraded patients showed a median OS of 24 months. Therefore, by using this easy-applicable approach we were able to detect a group of patients labeled at present as having lower-risk disease but who presented an outcome much closer to that of higher-risk patients. In addition, our approach allowed a better distribution of patients, as lower-risk patients, including those classified into the intermediate risk category, showed longer survivals than previously whereas higher-risk patients maintained the outcomes expected in this poor prognostic group (estimated median OS inferior to 20 months 33%, and very high risk: 31%; proportion of patients died with AML).
The final recommendation of authors was to assess these patients within both lower-and higher-risk future treatment protocols to conveniently define the best risk-adapted strategy in this subset of patients. comes if the patient with a higher predicted risk dies first. 23 The Cindex is the ratio of the number of concordant predictions and the set of all possible pairs. In other words, if one patient is IPSS-R "low" and another is "high," we would expect that the "low" lives longer than the "high." Therefore, taking into account the way that patients are compared, we can expect a high rate of mistakes when predicting overall survival in MDS. For example, a "discordant" pair would be generated if a "low" risk IPSS-R patient diagnosed at 87 years who died after 1 year of diagnosis due to an ischemic stroke was compared to an "intermediate" risk patient diagnosed at 55 years who died with AML after 2 years of diagnosis. In this regard, the accuracy of C-statistics in predicting AML evolution could give a better value of the outcome prediction of MDS prognostic scores, since AML evolution is the outcome more closely related with disease evolution. In this respect, our approach has been especially useful for the improvement in the detection of patients at risk of dying with AML. Nevertheless, it is not exempt of difficulties since this outcome is restricted to a limited number of patients. In its original description, the IPSS-R showed an evident improvement in prognostic power in terms of overall survival when compared to the IPSS, nevertheless the improvement in terms of AML prediction was slight, since 2% of patients were better predicted by using IPSS-R instead of IPSS (Dxy: 0.52 vs. 0.48, C-index: 0.76 vs. 0.74; IPSS-R vs.
IPSS respectively). 2 For all these reasons, the results derived from Cstatistics in MDS, although valuable, should be interpreted with caution and these never should overcome the clinical sense.
In conclusion, our method allowed a better risk stratification of patients, by permitting a more precise identification of lower-and higher-risk patients, the main aim of any MDS prognostic score. Our data strongly support the use of NEC as the denominator for BM blast percentage calculation.
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